Clinical Trials Initiated by the Clinician
In the majority ofcases clinical trials are promoted by the manufacturer of the drug substance to be evaluated. In some instances, however, a clinical trial may be initiated by a doctor who wishes to evaluate a new drug or an established drug in a new indication, or to administer the drug by a different route. In the latter circumstances, the doctor may wish to obtain this preparation from a manufacturer and before he can do this he must either hold a clinical trial certificate for the trial or have applied for, and obtained from the Licensing Authority, exemption from the need to hold such a certificate. No doctor requires a clinical trial certificate to conduct a clinical trial on any established drugs used in the indications for which the drug was approved for marketing. Exemption from the need to hold a clinical trial certificate would be required if he had approached the manufacturer to formulate identical capsules or tablets of one or more agents for the purpose of conducting a double blind study. A clinical trial certificate is not required if the doctor wishes to use a new unmarketed drug purely for therapeutic purposes for an individual named patient. REFERENCES British Medical Journal (1964) Brain to Bottle Time The title of this paper is not an accidental reversal of what might seem to be a more interesting measurement, nor was it devised while the brain was influenced by the bottle! Most clinicians will already possess some understanding of the methods by which a new drug is clinically evaluated before the licence to market the product is granted, and this paper considers the earlier development that turns a chemical compound from an idea in the brain to a potentially useful drug in the clinical trial bottle.
The first stage involves getting the chemical compound from flask or retort into a form suitable for administration: most drugs are finally presented in solid form as base or salt and are then made up in a formulation suitable for administration. Predevelopment stability examines the stability of the compound in different conditions: the compound is usually stored in glass bottles at varying degrees of temperature from freezing to tropical heat, and at intervals the samples are analysed to check whether or not there has been any physical or chemical deterioration. One important analytical aspect of this work ensures that in the final formulation there is no contaminant material arising either from the manufacturing process or produced as a result of storage.
Pharmaceutical formulation is a lengthy process aimed at producing a suitable dosage forminjection, tablet, capsule, aerosol, suppository, cream, ointment or whatever else is required. This is the area in which the 'culinary art' of the pharmacist is seen at its best and is probably the aspect that clinicians appreciate least. It is important to realize that when a particular drug is prescribed by the physician the patient does not receive that drug alone but a formulation containing the active constituent. The importance of formulation is now being increasingly recognized and some examples have achieved the status of classics, for instance the importance of particle size on the absorption of cortisone or griseofulvin. Then there was the fairly recent tragedy involving phenytoin in Australia when the alteration of one excipient dramatically increased the bioavailability of the drug; more recently still the differing bioavailability of digoxin from different batches and formulations has been the subject of intensive study.
Drugs made up for systemic administration are not necessarily simple solutions but may contain substances to improve the stability of the product, for example, an antioxidant. Occasionally these additional substances cause pain on injection, histamine release or thrombophlebitis; but the alternative, leaving them out of the formulation, may result in a product with an unacceptably short shelf life or with special storage characteristics (for example, succinylcholine requiring storage in the refrigerator) or require that the solution be made up freshly on each occasion. The type of solution may also be important, aqueous solutions being absorbed more readily after intramuscular injection than either colloids or suspensions.
Oral dosage forms may require extensive formulation so that the powder exhibits satisfactory flow characteristics for production and compression into tablets: starch, lactose, magnesium or calcium salts, and cellulose are all commonly used and the British Pharmacopeia (BP) lays down minimum standards for tests of tablet disintegration. Recently the US Pharmacopeia (USP) has described tablet dissolution tests which it is hoped will correlate with the in vivo bioavailability data. Depending on the physical properties of the active ingredient and of the formulated product, tablets can be made in different shapes to accommodate relatively large doses within a small bulk size. To disguise Section ofAna?sthetics the taste, tablets may be film coated or sugar coated, while a hard enteric coating will delay disintegration in the stomach: tablets containing two active constituents may be simple mixtures or, if the constituents are incompatible, one may be placed as a core inside the other, or they may be layered. Capsules avoid many of these difficulties and are being increasingly used, as are new techniques such as microencapsulation to provide a 'timed release' pattern.
As each new formulation is devised it has to be checked for stability and examined at regular intervals for physical and chemical deterioration, but for animal studies at least, formulation is not always a problem. Pharmacological studies are undertaken to evaluate the activity of the drug and to compare this activity to that of known standard compounds. However, the responsibility of the Committee on Safety of Medicines lies, as the name implies, in assessing the safety of the drug, and their requirements have already been described. This area, toxicology and teratology, is perhaps the most controversial of all the areas of new drug development. Last year, Dr W C Wescoe, formerly dean of the Medical School and vice-chancellor of the University of Kansas, said at a National Academy of Sciences forum that the experimental feeding of high concentrations of a particular substance, as a caricature of what man conceivably could ingest, in addition to being toxicologically naive, also ignored basic pharmacologic principles. For example, assuming that a 12 oz can of soft drink contained 0.25-1 g of sodium cyclamate, in order to ingest an amount of cyclamate comparable to that causing effects in rats and mice, an adult man would have to drink from 138-552 cans each day: or again, in order to consume oil of calamus in a quantity comparable to that shown to cause effects in rats a person would need to drink 250 quarts of vermouth each day.
If properly conducted, however, these tests can be meaningful and useful: to begin with it is necessary to know the metabolic pathway of the drug in the different animal species so that the results can be correctly interpreted. These studies are most commonly conducted in rats, rabbits or dogs, although primates are being used more frequently than before. Cats, being unable to form glucuronide conjugates, are not used in these studies, but a knowledge of this metabolic defect relative to man may explain pharmacological findings which seem to be bizarre. Also the pharmacokinetics of a base such as amphetamine are markedly different in the rabbit with its alkaline urine from those in man with his acid urine.
The toxicological tests are conducted using the route of administration which it is planned that man will use, and several dose levels are studied to cover the dose range anticipated for man. Studies to establish the LD50, that is the dose which is lethal to 50 % of the treated animals, give a guide to the therapeutic ratio and total toxicity of the compound, and of course, each study involves not only the treated animals but also an identical control group. The problem of obtaining identical controls has led to a search for animals that give birth to twins, triplets or quads and some centres now use marmosets, a primate that always has identical twins. A recent serious suggestion named the 9-banded armadillo, which has identical quads, as being the most useful mammal for these studies, but the proposer did not apparently consider the difficulty of obtaining or housing these burrowing creatures. The studies are conducted for 30 days and 90 days, the animals being killed at the end of the study and a full pathological examination being made on each animal. During the course of the studies routine biochemical and hematological monitoring is performed at regular intervals, and analysis of these data, together with the thousand or so slides that have to be examined can effectively extend the time for a further three months before the final report is complete.
The large mammals, such as dogs, require a period of acclimatization in their new surroundings before they can be used in the studies, and during this time and the study itself they have to be fed, exercised, weighed, cleaned, and the cages cleaned. The cost of this is somewhere in the range of £250-£400 for each animal, and the cost of a 30-day study is £500£700 per animal, while a 90-day study costs £650-£850: if the drug can be mixed in the food this obviously saves personnel time and is therefore cheaper than giving the drug by gavage or by injection, but has the disadvantage that dosing cannot be guaranteed to be accurate. A 30-day study in rats will cost £30-£50 for each animal and a 90-day study will cost £40-£70 per rat; a 90-day study in monkeys costs approximately £1000 per animal. Clearly these costs will vary considerably with the numbers involved, the amount of work, and the conditions under which the animals are kept.
Reproductive studies, involving usually the rat and the rabbit, may extend to three generations and will always involve fertility studies in the male and pre-and post-natal studies in the female. Rat studies cost £30£50 per animal, increasing to £100-£150 for a three-generation study, while a rabbit will cost £70-£90 per animal. The litters are born by Caesarean section and, according to the study requirements, the animals and offspring are killed and examined both macioscopically and microscopically for defects. Again, control groups are used for each study.
Once the drug has successfully passed these tests it is almost ready for clinical trial: during the 9 585 toxicological studies work on formulation, stability, alternative routes of synthesis and chemical analysis will have continued and only when the drug is clearly seen to be worth further investigation will it be given to man in the first human volunteer studies. These are designed to provide information on the blood levels reached, that is the bioavailability from the different formulations, and the pharmacokinetics of the drug in man. At this stage it may not be given to subjects suffering from the disease for which the drug is indicated, even although such subjects volunteer, but it is followed extensively at different dose levels in normal man until sufficient information is obtained. Finally, all the data obtained is submitted to the Committee on Safety of Medicines and the Clinical Trial Certificate requested; at this time the supplies for the first clinical trials are made and bottled. Depending on the drug, the time from the first synthesis or isolation to the granting of the Certificate may be anything from six to ten years, and it has been estimated that for every 1000 chemical compounds that are synthesized, 100 reach the initial pharmacological screening tests, 10 reach advanced screening and possibly clinical trial, and one new drug ultimately reaches the market. With that degree of handicap it is clear that if the supply of new drugs is not to dry up completely some way must be found to shorten the brain to bottle time.
Professor J W Dundee (Department ofAnasthetics, The Queen's University ofBelfast, Institute ofClinical Science, Grosvenor Road, Belfast BT12 6BJ) Clinical Trials in Anssthesia Although we think of clinical trials as a recent innovation, the Arabic scholar Avicenna (980-1037) recommended that 'the experimentation must be done with the human body, for the testing of a drug on a lion or a horse might not prove anything about its effect in man' (Bull 1959) .
If today one still wants proof of the importance of clinical trials in the evaluation of new drugs, it is difficult to better the words of Sir Hedley Atkins (1966) when he was President of the Royal College of Surgeons of England: 'There are many paths which lead to the acquisition of clinical knowledge that might profitably be explored but ... there is only one high road to an increase in therapeutic knowledge and that is the controlled clinical trial'.
The last three words in this quotation are vital. A 'trial' implies a scientific study, 'clinical' con-trasts with animal studies, while 'controlled' distinguishes a clinical trial from clinical impressions.
Based on this thinking, Maxwell (1969) has defined a clinical trial as a 'scientific experiment in which a therapy or therapeutic procedure is studied in patients'. Thus in anesthetics, a clinical trial could embrace study of a new technique, modification of an existing technique, a number of interrelated drugs or, in its simplest and most common form, be limited to one drug. We are here discussing drug trials.
Aims ofTrials
While one thinks of a clinical trial primarily as a study of a new drug, the aims are wider than this:
(1) Assessment of the activity of a new product which has a unique action or an action which is present to a unique degree.
(2) Comparison of drugs with similar actions but with varying potency and side effects. (3) More precise reassessment of drugs which are regarded as being well established.
In practice, the majority of clinical trials fall into the second group, where a Clinical Trials Certificate is required, but some involve only well established drugs. They are essential in the evaluation of new drugs and Fig 1 shows their relationship to other steps in the process of drug studies.
Before undertaking a clinical trial the investigator will have essential data from animal experiments and from pharmacological studies carried out on volunteers and have satisfied himself with the findings. Nevertheless, the initial results may point to the need for further data from these sources and to continue without this would be unethical. Thus embarking on a trial does not commit one to finishing it if untoward side-effects are found. Fig 1 suggests two types of clinical trialscontrolled and group. The latter may be multicentred and ideally it is organized by the person responsible for the initial study. This is not the same as 'limited release' or 'monitored release'. The initial controlled trial is designed to reduce variables to the minimum and in anesthesia it is often carried out only on fit patients. It may give results which are of little importance in everyday clinical practice: the observers are trained to detect small variations which are of no real clinical significance, the monitoring may be very sophisticated and, in subjective studies, the continuous presence of the physician can have a 'placebo' (pleasing) effect. In contrast, a 'group' trial with less rigorous patient-selection and the opinion of a large number of clinically-orientated observers is very helpful indeed and in anesthetic practice plays an important part in drug evaluation prior to general release.
